Kristen Fortney

First Trial Shows Best‑in‑Class NLRP3 Inhibitor Promise

Excited to complete our first clinical trial for BGE-102. Clinical data supporting best-in-class potential, built on new chemistry and a novel binding site targeting NLRP3 - a central driver of of chronic inflammation in aging. On to Phase 2!